D&D Pharmatech 347850.KQ · Stock Open D&D Pharmatech in new tab
D&D Pharmatech Analysis (347850.KQ)
Is D&D Pharmatech a good investment? D&D Pharmatech (347850.KQ) is currently trading at 83100.00 KRW.
Investor FAQ
Does D&D Pharmatech pay a dividend?
No, it does not currently pay a dividend.
What asset class is D&D Pharmatech?
D&D Pharmatech is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
D&D Pharmatech Inc. engages in the research and development and manufacturing of pharmaceuticals in South Korea. It develops oral peptides, such as MET-002o, MET-224o, MET-097o, DD03, DD07, and DD14 programs for obesity indications in the development phase; injectable peptides, including DD01 for MASH indications; NLY12 and DD15 for obesity indications; and Pegsebrenatide (NLY01) for Parkinson's and Alzheimer's diseases. The company is also involved in the development of TLY012, an injectable protein for systemic sclerosis, liver fibrosis, and chronic pancreatitis indications; NLY02, an oral small molecule for PD and AD indications; and P4M01 for anti-microbial peptide indications. In addition, it develops PMI07, PMI05, and PMI06 for solid tumor imaging biomarker indications; and PMI04 for neuroinflammation indications. The company was founded in 2014 and is based in Seongnam-si, South Korea.
| Split Date | Split Ratio to 1 |
|---|---|
| Nov. 13, 2025 | 4.000000 |
Community Discussion